We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.8B
AUM Growth
+$1.74M
Cap. Flow
+$81.8M
Cap. Flow %
0.36%
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$137M
2
PACB icon
Pacific Biosciences
PACB
+$66.5M
3
KOD icon
Kodiak Sciences
KOD
+$50.2M
4
BLUE
bluebird bio
BLUE
+$50.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$34M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$144M
2
ADCT icon
ADC Therapeutics
ADCT
+$34.5M
3
AMRN
Amarin Corp
AMRN
+$22.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
NVTA
Invitae Corporation
NVTA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GMDA
101
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$2.39M 0.01%
610,626
– –
CYPH
102
Cypherpunk Technologies Inc
CYPH
$153M
$2.24M 0.01%
55,971
– –
SERA icon
103
Sera Prognostics
SERA
$84.4M
$2.24M 0.01%
+201,562
New +$2.09M
SNDX icon
104
Syndax Pharmaceuticals
SNDX
$1.75B
$2.12M 0.01%
+110,729
New +$1.85M
LOGC
105
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$2.07M 0.01%
451,478
– –
EVFM
106
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$1.99M 0.01%
179,807
– –
TCRR
107
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$1.5M 0.01%
176,461
– –
TARA icon
108
Protara Therapeutics
TARA
$228M
$1.38M 0.01%
199,671
– –
INZY
109
DELISTED
Inozyme Pharma
INZY
$1.24M 0.01%
106,999
– –
KZR
110
DELISTED
Kezar Life Sciences
KZR
$1.21M 0.01%
13,968
– –
PASG icon
111
Passage Bio
PASG
$14.3M
$1.17M 0.01%
5,858
– –
AFMD
112
DELISTED
Affimed
AFMD
$1.02M ﹤0.01%
16,461
– –
SRZNW
113
DELISTED
Surrozen Inc Warrant
SRZNW
$950K ﹤0.01%
+833,333
New +$1.15M
OYST
114
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$728K ﹤0.01%
61,424
– –
BLCM
115
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$727K ﹤0.01%
249,123
– –
MREO
116
Mereo BioPharma
MREO
$46.4M
$708K ﹤0.01%
292,692
-2,166,707
-88% -$5.74M
ADCT icon
117
ADC Therapeutics
ADCT
$127M
– –
-1,418,107
Closed -$34.5M
APLS
118
DELISTED
Apellis Pharmaceuticals
APLS
– –
-2,271,917
Closed -$144M
ASMB icon
119
Assembly Biosciences
ASMB
$700M
– –
-175,718
Closed -$8.18M
KRRO icon
120
Korro Bio
KRRO
$194M
– –
-1,111
Closed -$553K
PTGX icon
121
Protagonist Therapeutics
PTGX
$9.99B
– –
-455,276
Closed -$20.4M
SPRY icon
122
ARS Pharmaceuticals
SPRY
$547M
– –
-238,095
Closed -$7.36M
SYRS
123
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-6,550
Closed -$357K
ORTX
124
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-119,200
Closed -$5.23M
ISEE
125
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,406,037
Closed -$8.87M
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2021 Portfolio in Review

As of Q3 2021, Julian Baker held 132 positions worth $22.8B, up 0.01% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker's Q3 2021 filing shows 12 new, 20 increased, 6 reduced and 10 closed positions. Its largest new stake was Surrozen: 166,667 shares worth $17.7M. The largest sale was Apellis Pharmaceuticals, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2021 buy was Surrozen: 166,667 shares worth $17.7M.
  • Julian Baker added most to Ascendis Pharma A/S in Q3 2021, an estimated $137M increase.
  • Julian Baker's biggest Q3 2021 reduction was Amarin Corp, cutting an estimated $22.6M.
  • Julian Baker fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $144M.
  • Julian Baker's ten largest holdings make up 83% of its $22.8B portfolio in Q3 2021.
  • Julian Baker opened 12 new positions and closed 10 in Q3 2021.
  • Julian Baker's portfolio value rose 0.01% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.